

Narrative Review

Exploring the Cardio-Protective Effect of Bioactive Compounds Present in Ginger, Garlic, and Turmeric

Amna Muneer¹, Areej Iqbal Awan¹, Muhammad Hamza^{1*}, Sami Ali Babekir², Waleed Fahad Alhujaili³, Saliha Naeem⁴, Fizza Saleem⁵

¹Department of Nutritional Sciences, Government College University Faisalabad, 38000, Punjab, Pakistan.

²Department of Rehabilitation Science, Al-Neelain University, 11113, Sudan.

³Department of Biological Sciences, College of Science, Taibah University, Al Madinah Al Munawwarah, 41321, Saudi Arabia.

⁴Department of Food, Nutrition and Dietetics, Nur International University, Lahore, 55150, Punjab, Pakistan.

⁵Department of Food Science and Technology, Jinnah University for Women, Karachi, 74600, Sindh, Pakistan.

*Corresponding Author: Muhammad Hamza; Email: muhammadhamza6171@gmail.com

Conflict of Interest: None.

Muneer A., et al. (2024). 4(1): DOI: <https://doi.org/10.61919/jhrr.v4i1.699>

ABSTRACT

Background: Cardiovascular diseases (CVDs) are the leading cause of mortality globally, with lifestyle and dietary habits playing crucial roles in their development and progression. Spices such as ginger, garlic, and turmeric have been traditionally recognized for their health benefits, attributed to their rich content of bioactive compounds. These spices offer potential therapeutic strategies for managing and preventing CVDs through various mechanisms, including anti-inflammatory, antioxidant, hypo-lipidemic, and anti-thrombotic properties.

Objective: This review aims to synthesize current evidence on the cardioprotective effects of ginger, garlic, and turmeric, focusing on their impact on lipid profiles, endothelial function, and overall cardiovascular risk factors.

Methods: A comprehensive search of databases such as PubMed, Scopus, and Web of Science was conducted to identify relevant studies published up to 2023. Criteria for inclusion encompassed clinical trials and observational studies examining the effects of ginger, garlic, and turmeric on CVD risk factors. Data on study design, population, intervention, outcomes, and conclusions were extracted and synthesized.

Results: The review included studies that reported beneficial effects of ginger, garlic, and turmeric on cardiovascular health. Specifically, these spices were found to improve lipid profiles by reducing levels of total cholesterol, low-density lipoprotein (LDL), and triglycerides, while increasing high-density lipoprotein (HDL). Furthermore, they exhibited anti-inflammatory and antioxidant activities, which are vital in mitigating endothelial dysfunction and reducing cardiovascular risk.

Conclusion: Ginger, garlic, and turmeric possess significant potential in reducing CVD risk through multiple mechanisms. Their inclusion in the diet may offer a natural and complementary approach to conventional CVD therapies. However, further large-scale, randomized controlled trials are necessary to confirm these findings and facilitate the integration of these spices into medical practice for CVD prevention and management.

Keywords: Cardiovascular diseases, ginger, garlic, turmeric, bioactive compounds, lipid profile, anti-inflammatory, antioxidant.

INTRODUCTION

Cardiovascular diseases (CVDs) represent a significant global health challenge, emerging as the leading cause of mortality in developed countries and anticipated to become the primary health concern worldwide. This group of disorders, encompassing peripheral artery disease, venous diseases, stroke, hypertension, and arteriosclerosis, is markedly influenced by lifestyle and dietary habits. A diet rich in processed sugars, refined foods, sodium, and saturated fats, coupled with insufficient intake of whole grains, fiber, nuts, legumes, fish, fruits, and vegetables, has been identified as a key risk factor for the development of CVDs (1,2,3). Additionally, factors such as sedentary lifestyles, obesity, stress, and smoking further contribute to the heightened risk associated with these diseases. Recent research has highlighted inflammation as a critical risk factor for cardiovascular conditions, including coronary artery disease and atherosclerosis, with elevated levels of high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) being indicative of increased risk (4). Similarly, dyslipidemia, characterized by elevated levels of low-density lipoprotein (LDL) and

triacylglyceride (TAG) and decreased levels of high-density lipoprotein cholesterol (HDL-C), is also a contributing factor to CVD risk (5).

In the context of dietary interventions aimed at mitigating CVD risk, the role of spices, with their long history of medicinal use, is particularly noteworthy. Spices have been employed for centuries to treat a wide array of conditions, from common colds to liver diseases and bacterial infections, owing to their potent anti-inflammatory, antioxidant, chemopreventive, and immunomodulatory properties (6). Among these, turmeric (*Curcuma longa*), ginger (*Zingiber officinale*), and garlic (*Allium sativum*) are especially prominent, largely due to their phytochemical content, including curcuminoids, gingerol, and sulfur-containing compounds, respectively (7). These components have been the subject of extensive research, suggesting their significant role in reducing risk factors critical to the development and progression of CVDs, such as oxidative stress, inflammation, and metabolic dysregulation. Consequently, this review aims to explore the mechanisms by which these spices may confer cardioprotective benefits, focusing on their potential to influence the risk factors associated with cardiovascular diseases, and thereby proposing an integrative approach to prevention and treatment.




Figure 1. Hypolipidemic effect of ginger




Figure 2. Effect of Garlic on reducing the risk of CVDs

MATERIAL AND METHODS

In conducting this narrative review, a thorough literature search was orchestrated to discern studies pertinent to evaluating the impacts of ginger, garlic, and turmeric on cardiovascular diseases (CVDs). The endeavor embraced a design structured to encompass an extensive temporal spectrum, with the duration of study identification spanning from January 2000 to December 2023. This broad temporal range was selected to capture the evolution of understanding regarding the cardiovascular effects of these spices.

The review was guided by a PICO (Population, Intervention, Comparator, Outcome) framework structured question: In adults with or at risk of CVDs, how do the active components of ginger, garlic, and turmeric, compared to no intervention or placebo, affect clinical cardiovascular outcomes? This question informed the development of search strategies, which were meticulously crafted to ensure comprehensive retrieval of relevant studies.

Search strategies incorporated a blend of keywords and MeSH terms tailored to the nuances of each database. The terms included "ginger", "garlic", "turmeric", "cardiovascular diseases", "atherosclerosis", "hypertension", "anti-inflammatory effects", "antioxidant effects", and "clinical outcomes". Boolean operators (AND, OR) were deployed to refine the search.

Research databases constituted the cornerstone of this review, with searches conducted across PubMed, Scopus, Web of Science, and the Cochrane Library, ensuring a broad and diverse collection of scientific literature. The selection process was underpinned by explicit inclusion and exclusion criteria. Studies were included if they were peer-reviewed, involved human subjects, examined the effects of ginger, garlic, or turmeric on CVD or its risk factors, and reported clinical outcomes. Exclusion criteria were non-English language publications, studies on animals, and those focusing on unrelated interventions or outcomes.

Validation and synthesis of the identified studies were achieved through a rigorous process. Each study was independently assessed by two reviewers for relevance and quality, with discrepancies resolved through consensus or consultation with a third reviewer. The data from eligible studies were then synthesized, focusing on the active components, mechanisms of action, and observed clinical outcomes.

Ethical considerations were paramount, given the review’s focus on human health outcomes. While the nature of a narrative review does not involve primary data collection from human participants, ensuring the ethical conduct of the included studies was essential. Therefore, only studies that reported adherence to ethical guidelines and had obtained appropriate ethical approvals were considered.

RESULTS

The analysis of the gathered data from various studies offers compelling insights into the cardiovascular effects of ginger, garlic, and turmeric on different patient demographics. The findings suggest a significant impact of these natural substances on lipid profiles, blood pressure, and overall cardiovascular health, as evidenced by the studies cited.

Ginger supplementation was investigated across a spectrum of cardiovascular conditions. In hyperlipidemic non-diabetic patients, a daily intake of 3g of ginger over 45 days resulted in notable reductions in LDL, total cholesterol (TC), and VLDL levels compared to a placebo, indicating ginger's potential in improving lipid profiles (52). Similarly, Mazidi et al. (53) observed that a 30-day consumption of 3g/day of ginger substantially lowered LDL and TC in hyperlipidemic patients aged 35-60 years. Further, ginger's efficacy was also demonstrated in atherosclerosis patients aged 40-70 years, where a daily dose of 1600mg for two months led to reductions in VLDL, triglycerides (TG), and body weight when compared to a placebo group (54), reinforcing ginger's role in cardiovascular health.

Garlic's cardiovascular benefits were highlighted in several studies. Coronary heart disease patients aged 40-65 years who were administered Allicor, a formulation containing 150mg of garlic powder, twice daily for 12 months, experienced significant decreases in LDL levels and overall CVD risk (55). Kojuri et al. (56) compared the effects of enteric-coated garlic powder tablets (400mg garlic+1mg allicin, twice daily) in hyperlipidemic patients against ginger and placebo groups, observing notable improvements in TC, LDL, HDL, and TG levels, which suggests garlic's multifaceted beneficial impact on lipid metabolism.

Turmeric also showed promising results in cardiovascular health improvement. In hyperlipidemic type 2 diabetes mellitus patients, the daily intake of 2100mg powdered rhizome of turmeric for eight weeks led to significant decreases in body weight, TG, LDL-c, and TC. Pashine et al. (59) further validated turmeric's efficacy in overweight hyperlipidemic subjects, where an aqueous extract of turmeric (1.4mg/day) over three months resulted in significant reductions in TC, LDL, TG, LDL-c, and VLDL-c levels when compared to a placebo group. Lastly, non-alcoholic fatty liver disease patients who received 2g/day of turmeric oral capsules for eight weeks showed decreases in LDL, HDL, and malondialdehyde (MDA) levels, pointing towards turmeric's antioxidant and lipid-lowering effects.

Population	Intervention	Duration	Outcomes	Reference
Hyperlipidemic non-diabetic patients (n=45 ginger, n=40 placebo)	3g/day ginger	45 days	LDL↓, TC↓, VLDL↓ (Ginger vs. Placebo)	Alizadeh-Navaei et al., (52)
Hyperlipidemic patients (n=100), 35-60 years	3g/day ginger	30 days	LDL↓, TC↓	Mazidi et al., (53)
Atherosclerosis patients (n=72), 40-70 years	1600mg/day ginger	2 months	VLDL↓, TG↓, weight↓ (Ginger vs. Placebo)	Babaahmadi-Rezaei, (54)
Coronary heart disease patients (n=51), 40-65 years (men, women)	Allicor (coated tablets containing 150mg garlic powder) 1 tablet twice a day	12 months	LDL↓, CVD risk ↓	Sobenin et al., (55)
Hyperlipidemic patients (n=150) (n=50 ginger, n=50 antheum, n=50 placebo)	Enteric coated garlic powder tablet (400mg garlic+1mg allicin) twice daily	-	TC↓, LDL↓, HDL↑, TG ↓ (Ginger vs. Antheum)	Kojuri et al., (56)
Hypercholesterolemia patients (n=67)	250mg/day aged black garlic (AGE)	6 weeks	DBP↓ (Hypercholesterolemia vs. healthy)	Valls et al., (57)
Hyperlipidemic type 2 diabetes mellitus patients (n=80)	2100mg powdered rhizome of turmeric daily	8 weeks	Body weight ↓, TG↓, LDL-c↓, TC↓ (Hyperlipidemic vs. placebo)	Adab et al., (58)

Overweight hyperlipidemic subjects (n=120)	Aqueous extract of turmeric 1.4mg/day	of 3 months	TC↓, LDL↓, TG↓, LDL-c↓, VLDL-c↓ (Treatment vs. placebo)	Pashine et al., (59)
Non-alcoholic fatty liver disease patients (n=64)	2gr/day turmeric capsule	oral 8 weeks	LDL↓, HDL↓, MDA↓ (Turmeric vs. placebo)	Jarhahzadeh et al., (60)

DISCUSSION

The investigation into the cardioprotective properties of ginger, garlic, and turmeric has unveiled significant insights into their therapeutic potential, particularly regarding cardiovascular health. These findings, when juxtaposed with existing literature, delineate a compelling narrative of the bioactive compounds present in these spices and their multifaceted roles in mitigating cardiovascular disease (CVD) risk factors.

Ginger, renowned for its oleoresin that harbors a plethora of bioactive compounds, chiefly gingerols, has been highlighted for its anti-inflammatory and antioxidant prowess (8,9). The transition of gingerols to shogaols and their subsequent conversion to paradol accentuates the dynamic nature of ginger's phytochemistry and its implications for health (10). The suppression of inflammatory pathways, including STAT, NF-κB, and MAPK, by ginger's bioactive constituents underscores its potential in countering inflammation-driven conditions like CVDs (12). Clinical trials have corroborated ginger's efficacy in dampening the symptoms of CVDs and bolstering immune defenses by modulating NF-κB and upregulating genes associated with cardiovascular health (13).

Similarly, garlic's utility in cardiovascular disorders has been well-documented, with its organosulfur compounds, such as allicin, showcasing hypo-lipidemic and antihypertensive effects (23,24). The reduction of triglyceride levels and improvement in HDL and LDL ratios affirm garlic's role in lipid metabolism, while its antihypertensive benefits, attributed to hydrogen sulfide generation and allicin's action, further validate its therapeutic value (26-29).

Turmeric's curcuminoids, particularly curcumin, have exhibited notable anti-atherogenic, antioxidant, and anti-inflammatory activities. Curcumin's influence on lipid profiles and its capacity to enhance the LDL to HDL cholesterol ratio present a strong case for its anti-atherogenic properties (43-45). Additionally, the antioxidant and anti-inflammatory properties of turmeric, evidenced through various studies, suggest a comprehensive approach towards mitigating atherosclerosis and its associated risks (46-51).

The strengths of the discussed studies lie in their detailed exploration of the mechanisms underlying the beneficial effects of these spices. However, limitations arise from the variance in study designs, populations, and dosages, which may introduce heterogeneity in outcomes. Moreover, the bioavailability of these compounds poses a challenge, potentially limiting their therapeutic efficacy.

Recommendations for future research include conducting large-scale, randomized controlled trials to establish standardized dosages and elucidate the long-term effects of these spices on cardiovascular health. Additionally, exploring the synergistic effects of these bioactive compounds and their bioavailability could yield novel insights into their therapeutic potential.

Ginger, garlic, and turmeric exhibit significant potential in mitigating cardiovascular risks through their anti-inflammatory, antioxidant, and hypo-lipidemic properties. These findings, aligned with existing literature, underscore the therapeutic value of these spices in cardiovascular health. Nonetheless, addressing the limitations through rigorous research is imperative to fully harness their potential, thereby contributing to the development of integrative strategies for CVD management and prevention.

CONCLUSION

In conclusion, the exploration into the cardioprotective effects of ginger, garlic, and turmeric illuminates their considerable potential in ameliorating cardiovascular disease risks. These spices, imbued with a wealth of bioactive compounds such as polyphenols, gingerol, organosulfur compounds, and curcumin, offer a multifaceted approach to natural medicinal benefits. Beyond their nutritional value, garlic, ginger, and turmeric manifest a spectrum of therapeutic properties, including anti-inflammatory, antioxidant, circulatory enhancement, immune-boosting, and anti-thrombotic effects. Clinical studies affirm that incorporating these spices into the diet can positively alter lipid profiles, enhance endothelial function, and mitigate overall cardiovascular risk factors. Nonetheless, the healthcare implications of these findings underscore the need for further research and clinical trials. Such endeavors are vital to substantiate the therapeutic utility of these spices, paving the way for their integration into conventional medical practice and the broader spectrum of preventive healthcare strategies.

REFERENCES

1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. *Circulation*. 2018 Mar 20;137(12):e67-492.
2. Anand SS, Hawkes C, De Souza RJ, Mente A, Dehghan M, Nugent R, et al. Food consumption and its impact on cardiovascular disease: importance of solutions focused on the globalized food system: a report from the workshop convened by the World Heart Federation. *J Am Coll Cardiol*. 2015 Oct 6;66(14):1590-614.
3. Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L, Lichtenstein AH, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. *Circulation*. 2010 Jul 27;122(4):406-41.
4. Shaito A, Thuan DT, Phu HT, Nguyen TH, Hasan H, Halabi S, et al. Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and safety. *Front Pharmacol*. 2020 Apr 7;11:509974.
5. Pourmasoumi M, Hadi A, Rafie N, Najafgholizadeh A, Mohammadi H, Rouhani MH. The effect of ginger supplementation on lipid profile: A systematic review and meta-analysis of clinical trials. *Phytomedicine*. 2018 Apr 1;43:28-36.
6. Kulczyński B, Gramza-Michałowska A. The importance of selected spices in cardiovascular diseases. *Adv Hyg Exp Med*. 2016 Nov 14;70:1131-41.
7. Madkor HR, Mansour SW, Ramadan G. Modulatory effects of garlic, ginger, turmeric and their mixture on hyperglycaemia, dyslipidaemia and oxidative stress in streptozotocin–nicotinamide diabetic rats. *Br J Nutr*. 2011 Apr;105(8):1210-7.
8. Bode AM, Dong Z. The amazing and mighty ginger. In: *Herbal Medicine: Biomolecular and Clinical Aspects*. 2nd edition. 2011.
9. Roudsari NM, Lashgari NA, Momtaz S, Roufogalis B, Abdolghaffari AH, Sahebkar A. Ginger: A complementary approach for management of cardiovascular diseases. *Biofactors*. 2021 Nov;47(6):933-51.
10. Stoner GD. Ginger: is it ready for prime time?. *Cancer Prev Res*. 2013 Apr 1;6(4):257-62.
11. Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, et al. Bioactive compounds and bioactivities of ginger (*Zingiber officinale* Roscoe). *Foods*. 2019 May 30;8(6):185.
12. Morvaridzadeh M, Fazelian S, Agah S, Khazdouz M, Rahimlou M, Agh F, et al. Effect of ginger (*Zingiber officinale*) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. *Cytokine*. 2020 Nov 1;135:155224.
13. Arablou T, Aryaeian N, Valizadeh M, Hosseini A, Djalali M. The effect of ginger consumption on some cardiovascular risk factors in patients with type 2 diabetes mellitus.
14. Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: Pivotal roles in inflammation. *Biochim Biophys Acta Mol Basis Dis*. 2017 Feb 1;1863(2):585-97.
15. Morvaridzadeh M, Fazelian S, Agah S, Khazdouz M, Rahimlou M, Agh F, et al. Effect of ginger (*Zingiber officinale*) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials. *Cytokine*. 2020 Nov 1;135:155224.
16. Salaramoli S, Mehri S, Yarmohammadi F, Hashemy SI, Hosseinzadeh H. The effects of ginger and its constituents in the prevention of metabolic syndrome: A review. *Iran J Basic Med Sci*. 2022 Jun;25(6):664.
17. Bhandari U, Pillai KK. Effect of ethanolic extract of *Zingiber officinale* on dyslipidaemia in diabetic rats. *J Ethnopharmacol*. 2005 Feb 28;97(2):227-30.
18. ElRokh ES, Yassin NA, El-Shenawy SM, Ibrahim BM. Antihypercholesterolaemic effect of ginger rhizome (*Zingiber officinale*) in rats. *Inflammopharmacology*. 2010 Dec;18:309-15.
19. Mazidi M, Gao HK, Rezaie P, Ferns GA. The effect of ginger supplementation on serum C-reactive protein, lipid profile and glycaemia: a systematic review and meta-analysis. *Food Nutr Res*. 2016 Jan 1;60(1):32613.
20. Mohd Yusof YA. Gingerol and its role in chronic diseases. In: *Drug discovery from mother nature*. 2016:177-207.
21. Alizadeh-Navaei R, Roozbeh F, Saravi M, Pouramir M, Jalali F, Moghadamnia AA. Investigation of the effect of ginger on the lipid levels. *Saudi Med J*. 2008;29(9):1280-4.
22. Duhamel TA, Xu YJ, Arneja AS, Dhalla NS. Targeting platelets for prevention and treatment of cardiovascular disease. *Expert Opin Ther Targets*. 2007 Dec 1;11(12):1523-33.
23. Londhe VP, Gavasane AT, Nipate SS, Bandawane DD, Chaudhari PD. Role of garlic (*Allium sativum*) in various diseases: An overview. *J Angiogenes Res*. 2011;12(13):129-34.
24. Tattelman E. Health effects of garlic. *Am Fam Physician*. 2005 Jul 1;72(01):103-6.
25. Shang A, Cao SY, Xu XY, Gan RY, Tang GY, Corke H, et al. Bioactive compounds and biological functions of garlic (*Allium sativum* L.). *Foods*. 2019 Jul 5;8(7):246.

26. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T. Effect of garlic on blood pressure: a systematic review and meta-analysis. *BMC Cardiovasc Disord.* 2008 Dec;8:1-2.
27. Ried K, Frank OR, Stocks NP. Aged garlic extract reduces blood pressure in hypertensives: a dose–response trial. *Eur J Clin Nutr.* 2013 Jan;67(1):64-70.
28. Siegel G, Walter A, Engel S, Walper A, Michel F. Pleiotropic effects of garlic. *Wien Med Wochenschr.* 1999 Jan 1;149(8-10):217-24.
29. Karagodin VP, Sobenin IA, Orekhov AN. Antiatherosclerotic and cardioprotective effects of time-released garlic powder pills. *Curr Pharm Des.* 2016 Jan 1;22(2):196-213.
30. Asdaq SM. Antioxidant and hypolipidemic potential of aged garlic extract and its constituent, s-allyl cysteine, in rats. *Evid Based Complement Alternat Med.* 2015 Oct;2015.
31. Sobenin IA, Myasoedova VA, Il'tchuk MI, Zhang DW, Orekhov AN. Therapeutic effects of garlic in cardiovascular atherosclerotic disease. *Chin J Nat Med.* 2019 Oct 1;17(10):721-8.
32. Orekhov AN, Oishi Y, Nikiforov NG, Zhelankin AV, Dubrovsky L, Sobenin IA, et al. Modified LDL particles activate inflammatory pathways in monocyte-derived macrophages: transcriptome analysis. *Curr Pharm Des.* 2018 Jul 1;24(26):3143-51.
33. Lee DY, Li H, Lim HJ, Lee HJ, Jeon R, Ryu JH. Anti-inflammatory activity of sulfur-containing compounds from garlic. *J Med Food.* 2012 Nov 1;15(11):992-9.
34. Rodrigues C, Percival SS. Immunomodulatory effects of glutathione, garlic derivatives, and hydrogen sulfide. *Nutrients.* 2019 Jan 30;11(2):295.
35. Zamani Taghizadeh Rabe S, Ghazanfari T, Siadat Z, Rastin M, Zamani Taghizadeh Rabe S, Mahmoudi M. Anti-inflammatory effect of garlic 14-kDa protein on LPS-stimulated-J774A.1 macrophages. *Immunopharmacol Immunotoxicol.* 2015 Mar 4;37(2):158-64.
36. Kiesewetter H, Jung F, Pindur G, Jung EM, Mrowietz C, Wenzel E. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. *Int J Clin Pharmacol Ther Toxicol.* 1991 Apr 1;29(4):151-5.
37. Rahman K. Effects of garlic on platelet biochemistry and physiology. *Mol Nutr Food Res.* 2007 Nov;51(11):1335-44.
38. Verma RK, Kumari P, Maurya RK, Kumar V, Verma RB, Singh RK. Medicinal properties of turmeric (*Curcuma longa* L.): A review. *Int J Chem Stud.* 2018;6(4):1354-7.
39. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: From kitchen to clinic. *Mol Nutr Food Res.* 2013 Sep;57(9):1510-28.
40. Heath DD, Khwaja F, Rock CL. Curcumin content of turmeric and curry powders. *FASEB J.* 2004 Mar 23;18(4):A125.
41. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK. Stability of curcumin in buffer solutions and characterization of its degradation products. *J Pharm Biomed Anal.* 1997 Aug 1;15(12):1867-76.
42. Shehzad A, Rehman G, Lee YS. Curcumin in inflammatory diseases. *Biofactors.* 2013 Jan;39(1):69-77.
43. Cox FF, Misiou A, Vierkant A, Ale-Agha N, Grandoch M, Haendeler J, Altschmied J. Protective effects of curcumin in cardiovascular diseases—Impact on oxidative stress and mitochondria. *Cells.* 2022 Jan 20;11(3):342.
44. Ramirez-Tortosa MC, Mesa MD, Aguilera MC, Quiles JL, Baro L, Ramirez-Tortosa CL, Martinez-Victoria E, Gil A. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. *Atherosclerosis.* 1999 Dec 1;147(2):371-8.
45. Li X, Lu Y, Sun Y, Zhang Q. Effect of curcumin on permeability of coronary artery and expression of related proteins in rat coronary atherosclerosis heart disease model. *Int J Clin Exp Pathol.* 2015;8(6):7247.
46. Dikshit M, Rastogi L, Shukla R, Srimal RC. Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. *Indian J Med Res.* 1995 Jan 1;101:31-5.
47. Bengmark S, Mesa MD, Gil A. Plant-derived health—the effects of turmeric and curcuminoids. *Nutr Hosp.* 2009;24(3):273-81.
48. Jagetia GC, Aggarwal BB. “Spicing up” of the immune system by curcumin. *J Clin Immunol.* 2007 Jan;27:19-35.
49. Quiles JL, Aguilera C, Mesa MD, Ramirez-Tortosa MC, Baro L, Gil A. An ethanolic-aqueous extract of *Curcuma longa* decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. *Biofactors.* 1998 Jan 1;8(1-2):79-85.
50. Cox FF, Misiou A, Vierkant A, Ale-Agha N, Grandoch M, Haendeler J, et al. Protective effects of curcumin in cardiovascular diseases—Impact on oxidative stress and mitochondria. *Cells.* 2022 Jan 20;11(3):342.

51. Coban D, Milenkovic D, Chanet A, Khallou-Laschet J, Sabbe L, Palagani A, et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. *Mol Nutr Food Res*. 2012 Aug;56(8):1270-81.
52. Alizadeh-Navaei R, Roozbeh F, Saravi M, Pouramir M, Jalali F, Moghadamnia AA. Investigation of the effect of ginger on the lipid levels. *Saudi Med J*. 2008;29(9):1280-4.
53. Mazidi M, Gao HK, Rezaie P, Ferns GA. The effect of ginger supplementation on serum C-reactive protein, lipid profile and glycaemia: a systematic review and meta-analysis. *Food Nutr Res*. 2016;60:32613.
54. Babaahmadi-Rezaei H. The effect of ginger supplementation on the lipid profile, blood glucose, quality of life and functional capacity in patients with coronary artery disease.
55. Sobenin IA, Pryanishnikov VV, Kunnova LM, Rabinovich YA, Martirosyan DM, Orekhov AN. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. *Lipids Health Dis*. 2010;9:1-6.
56. Kojuri J, Vosoughi AR, Akrami M. Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients. *Lipids Health Dis*. 2007;6:1-5.
57. Valls RM, Companys J, Calderón-Pérez L, Salamanca P, Pla-Pagà L, Sandoval-Ramírez BA, et al. Effects of an optimized aged garlic extract on cardiovascular disease risk factors in moderate hypercholesterolemic subjects: a randomized, crossover, double-blind, sustained and controlled study. *Nutrients*. 2022 Jan;14(3):405.
58. Adab Z, Eghtesadi S, Vafa MR, Heydari I, Shojaii A, Haqqani H, Arablou T, et al. Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. *Phytother Res*. 2019 Apr;33(4):1173-81.
59. Pashine L, Singh JV, Vaish AK, Ojha SK, Mahdi AA. Effect of turmeric (*Curcuma longa*) on overweight hyperlipidemic subjects: Double-blind study. *Indian J Community Health*. 2012 Jun 30;24(2):113-7.
60. Jarhahzadeh M, Alavinejad P, Farsi F, Husain D, Rezazadeh A. The effect of turmeric on lipid profile, malondialdehyde, liver echogenicity and enzymes among patients with nonalcoholic fatty liver disease: a randomized double-blind clinical trial. *Diabetol Metab Syndr*. 2021;13:1-9.